中国医药科学
中國醫藥科學
중국의약과학
China Medicine and Pharmacy
2015年
18期
125-128
,共4页
贝那普利%慢性心力衰竭%疗效%脑钠素%高敏C反应蛋白%临床价值
貝那普利%慢性心力衰竭%療效%腦鈉素%高敏C反應蛋白%臨床價值
패나보리%만성심력쇠갈%료효%뇌납소%고민C반응단백%림상개치
Benner Pury%Chronic heart failure%Clinical effect%Brain natriuretic peptide%High sensitivity C reactive protein%Clinical value
目的：探讨贝那普利对慢性心力衰竭患者疗效及血浆脑钠素、高敏C反应蛋白的影响。方法选取本院2011年12月～2014年12月诊治的慢性心力衰竭患者189例，采用随机数字表法分为3组，63例患者实施常规治疗为对照组，63例患者加用贝那普利（2.5mg/次，2次/d）为A组，63例患者加用贝那普利（5mg/次，2次/d）为B组，比较3组患者心脏指标的改变情况、检测指标的改变情况、临床疗效、不良反应情况。结果治疗后，3组患者左室收缩末期内径、左室舒张末期内径、血浆脑钠素、高敏C反应蛋白均显著降低，左室射血分数、6min步行距离均显著增加。A组患者左室收缩末期内径、左室舒张末期内径、血浆脑钠素、高敏C反应蛋白均明显低于对照组，左室射血分数、6min步行距离、总有效率均明显高于对照组。B组患者左室收缩末期内径、左室舒张末期内径、血浆脑钠素、高敏C反应蛋白均明显低于对照组和A组，左室射血分数、6min步行距离、总有效率均明显高于对照组和A组。差异均有统计学意义（P＜0.05）。结论贝那普利是治疗慢性心力衰竭的有效药物，可显著降低血浆脑钠素、高敏C反应蛋白水平，提高心功能，疗效显著，具有较高的安全性，值得临床推广使用。
目的：探討貝那普利對慢性心力衰竭患者療效及血漿腦鈉素、高敏C反應蛋白的影響。方法選取本院2011年12月～2014年12月診治的慢性心力衰竭患者189例，採用隨機數字錶法分為3組，63例患者實施常規治療為對照組，63例患者加用貝那普利（2.5mg/次，2次/d）為A組，63例患者加用貝那普利（5mg/次，2次/d）為B組，比較3組患者心髒指標的改變情況、檢測指標的改變情況、臨床療效、不良反應情況。結果治療後，3組患者左室收縮末期內徑、左室舒張末期內徑、血漿腦鈉素、高敏C反應蛋白均顯著降低，左室射血分數、6min步行距離均顯著增加。A組患者左室收縮末期內徑、左室舒張末期內徑、血漿腦鈉素、高敏C反應蛋白均明顯低于對照組，左室射血分數、6min步行距離、總有效率均明顯高于對照組。B組患者左室收縮末期內徑、左室舒張末期內徑、血漿腦鈉素、高敏C反應蛋白均明顯低于對照組和A組，左室射血分數、6min步行距離、總有效率均明顯高于對照組和A組。差異均有統計學意義（P＜0.05）。結論貝那普利是治療慢性心力衰竭的有效藥物，可顯著降低血漿腦鈉素、高敏C反應蛋白水平，提高心功能，療效顯著，具有較高的安全性，值得臨床推廣使用。
목적：탐토패나보리대만성심력쇠갈환자료효급혈장뇌납소、고민C반응단백적영향。방법선취본원2011년12월～2014년12월진치적만성심력쇠갈환자189례，채용수궤수자표법분위3조，63례환자실시상규치료위대조조，63례환자가용패나보리（2.5mg/차，2차/d）위A조，63례환자가용패나보리（5mg/차，2차/d）위B조，비교3조환자심장지표적개변정황、검측지표적개변정황、림상료효、불량반응정황。결과치료후，3조환자좌실수축말기내경、좌실서장말기내경、혈장뇌납소、고민C반응단백균현저강저，좌실사혈분수、6min보행거리균현저증가。A조환자좌실수축말기내경、좌실서장말기내경、혈장뇌납소、고민C반응단백균명현저우대조조，좌실사혈분수、6min보행거리、총유효솔균명현고우대조조。B조환자좌실수축말기내경、좌실서장말기내경、혈장뇌납소、고민C반응단백균명현저우대조조화A조，좌실사혈분수、6min보행거리、총유효솔균명현고우대조조화A조。차이균유통계학의의（P＜0.05）。결론패나보리시치료만성심력쇠갈적유효약물，가현저강저혈장뇌납소、고민C반응단백수평，제고심공능，료효현저，구유교고적안전성，치득림상추엄사용。
Objective To investigate influence of plasma brain natriuretic peptide, high sensitive C reactive protein and clinical effect of Benner Pury in patients with chronic heart failure.Methods 189 patients with chronic heart failure were selected in hospital from December 2011 to December 2014, who were divided into three groups by random number table method. 63 patients received routine treatment as control group. 63 patients combined Benner Pury(2.5mg/time, 2 times/d) as group A. 63 patients combined Benner Pury(5mg/time, 2 times/d) as group B. Changes of cardiac indexes and detection indexes; clinical effect; adverse reactions were compared between three groups. ResultsAfter treatment, left ventricular end systolic diameter; left ventricular end diastolic diameter; plasma brain natriuretic peptide; high sensitive C reactive protein decreased significantly while left ventricular ejection fraction; 6 min walking distance increased significantly in three groups. Left ventricular end systolic diameter; left ventricular end diastolic diameter; plasma brain natriuretic peptide; high sensitive C reactive protein in group A were significantly lower than control group. Left ventricular ejection fraction; 6 min walking distance; total effective rate in group A were significantly higher than control group. Left ventricular end systolic diameter; left ventricular end diastolic diameter; plasma brain natriuretic peptide; high sensitive C reactive protein in group B were significantly lower than control group and group A. Left ventricular ejection fraction; 6 min walking distance; total effective rate in group B were significantly higher than control group and group A.Differences were statistically significant(P<0.05).Conclusion Benner Pury is an effective drug in treatment of chronic heart failure, which can significantly reduce plasma brain natriuretic peptide and high sensitive C reactive protein level, which can significantly improve heart function, which has significant clinical effect and high security, which is worthy of clinical use.
